Drug-induced Pisa syndrome under quetiapine

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 33, Issue 7, 2009, Pages 1286-1287

  Walder, Alice ^a   Greil, Waldemar ^a   Baumann, Pierre ^b  

^a Psychiatrische Privatklinik Sanatorium Kilchberg   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; GALANTAMINE; LORAZEPAM; OLANZAPINE; QUETIAPINE; TRAZODONE;

AGED; ALZHEIMER DISEASE; ANXIETY; BRAIN ATROPHY; CAROTID ARTERY OBSTRUCTION; CASE REPORT; CLINICAL FEATURE; COGNITIVE DEFECT; CONFUSION; DEGENERATIVE DISEASE; DEPRESSION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GLIOSIS; HUMAN; LETTER; NUCLEAR MAGNETIC RESONANCE IMAGING; PISA SYNDROME; RESTLESSNESS;

AGED; ANTIPSYCHOTIC AGENTS; COGNITION DISORDERS; DIBENZOTHIAZEPINES; DYSTONIA; FEMALE; HUMANS; SPASM;

EID: 69349093648     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2009.07.024     Document Type: Letter

References (16)

1. Colosimo C. Pisa syndrome in a patient with multiple system atrophy. Mov Disord 13 3 (1998) 607-609
2. Duggal H.S., Sivamony S., and Umapathy C. Pisa syndrome and atypical antipsychotics. Am J Psychiatry 161 2 (2004) 373
3. Ekbom K., Lindholm H., and Ljungberg L. New dystonic syndrome associated with butyrophenone therapy. Z Neurol 202 2 (1972) 94-103
4. Grohmann R., Engel R.R., Rüther E., and Hippius H. The AMSP drug safety program: methods and global results. Pharmacopsychiatry 37 Suppl 1 (2004) 4-11
5. Guy N., Raps A., and Assael M. The Pisa syndrome during maintenance antipsychotic therapy. Am J Psychiatry 143 (1986) 1492
6. Harada K., Sasaki N., Ikeda H., Nakano N., Ozawa H., and Saito T. Risperidone-induced Pisa syndrome. J Clin Psychiatry 63 2 (2002) 166
7. Huvent-Grelle D., Roche J., Gaxatte C., Dewailly P., and Puisieux F. Relation between Pisa syndrome and choline esterase inhibitors in a cohort of Alzheimer's disease patients. Presse Medicale 38 1 (2009) 150-153
8. Kwak Y.T., Han I.W., Baik J., and Koo M.S. Relation between cholinesterase inhibitor and Pisa syndrome. Lancet 24 355(9222) (2000) 2222
9. Meyer J.M. Antipsychotic safety and efficacy concerns. J Clin Psychiatry 68 Suppl 14 (2007) 20-26
10. Patel S., Tariot P.N., and Hamill R.W. Pisa syndrome without neuroleptic exposure in a patient with dementia of the Alzheimer type. J Geriatr Psychiatry Neurol 4 1 (1991) 48-51
11. Pilette W.L. Pisa syndrome or pleurothotonus. Am J Psychiatry (1987) 969-970
12. Rota E., Bergesio G., Dettoni E., and Demicheli C.M. Pisa syndrome during aripiprazole treatment: a case report. Prog Neuropsychopharmacol Biol Psychiatry 31 1 (2007) 286-287
13. Stübner S., Padberg F., Grohmann R., Hample H., Hollweg M., Hippius H., et al. Pisa syndrome (pleurothotonus): report of a multicenter drug safety surveillance project. J Clin Psychiatry 61 8 (2000) 569-574
14. Suzuki T., and Matsuzaka H. Drug-induced Pisa syndrome (pleurothotonus): epidemiology and management. CNS Drugs 16 3 (2002) 165-174
15. Suzuki T., Koizumi J., Moroji T., Sakuma K., Hori M., and Hori T. Clinical characteristics of the Pisa syndrome. Acta Psychiatr Scand 82 6 (1990) 454-457
16. Suzuki T., Kurita H., Hori T., Sasaki M., Baba A., Shiraishi H., et al. The Pisa syndrome (pleurothotonus) during antidepressant therapy. Biol Psychiatry 41 2 (1997) 234-236